Dogwood Therapeutics (DWTX) Stock: Buy, Sell, or Hold?
DWTX - Dogwood Therapeutics, Inc. Common Stock
$1.94
0.06 (3.19%)
▲
5d:
-17.8%
30d:
+0.78%
90d:
+23.57%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When DWTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: DWTX is down 17.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: DWTX is down 17.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: DWTX is currently trading at $1.94, which is considered slightly low relative to its 30-day fair value range of $1.90 to $2.51.
Technical Outlook: Technically, DWTX is in a uptrend. Immediate support is located at $1.83, while resistance sits at $2.74. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: DWTX scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.00 (+621.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DWTX is in a uptrend. Immediate support is located at $1.83, while resistance sits at $2.74. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: DWTX scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.00 (+621.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.90 -
$2.51
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 621.6% below Wall St target ($14.00)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.90 -
$2.51
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.83
Resistance Level
$2.74
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.05
Wall Street Target
$14.00
(+621.6%)
Share & Embed Analysis
Last updated: September 13, 2026 2:15 PM ET
Data refreshes hourly during market hours. Next update: 3:15 PM
Data refreshes hourly during market hours. Next update: 3:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DWTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
